Presentation is loading. Please wait.

Presentation is loading. Please wait.

The rules of run chart for determining nonrandom change.

Published byJan-Olof Sandberg Modified over 5 years ago

Similar presentations

Presentation on theme: "The rules of run chart for determining nonrandom change."— Presentation transcript:

1 The rules of run chart for determining nonrandom change.
The rules of run chart for determining nonrandom change. (A) Shift: six or more consecutive points lying on one side of the median. (B) Trend: five or more consecutive points either ascending or descending. (C) Run: either too few or too many crossings of the median line. (D) (see shaded areas) Astronomical point: a point on the graph that subjectively appears out of keeping with others (shaded areas). Rory Francis McQuillan et al. CJASN 2016;11: ©2016 by American Society of Nephrology

Download ppt "The rules of run chart for determining nonrandom change."

Similar presentations

Measurement for Improvement. Why we look at data graphed over time Change Made Change to process made in June.

Measurement for Improvement. Why we look at data graphed over time Change Made Change to process made in June.
Monitoring Improvement Using a Run Chart Priscilla Swanson, RN, CCM, CHC, CPHQ Nancy Siegel, MPH, PA-C June 10, 2013 QHOC meeting.

Monitoring Improvement Using a Run Chart Priscilla Swanson, RN, CCM, CHC, CPHQ Nancy Siegel, MPH, PA-C June 10, 2013 QHOC meeting.
1 A Focus on Measurement Part II. 2 Objectives  Explain the difference between common cause and special cause variation  Explain the purpose of a run.

1 A Focus on Measurement Part II. 2 Objectives  Explain the difference between common cause and special cause variation  Explain the purpose of a run.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Westgard rules 12s rule: the run is accepted when both control results are within 2 SD limits from the mean value 13s rule: the run is considered out.

Westgard rules 12s rule: the run is accepted when both control results are within 2 SD limits from the mean value 13s rule: the run is considered out.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Representative polyacrylamide/6% urea gels that demonstrate transferrin saturation (TSAT) for (A) a patient who was given the low-dosage (1.5 mg/kg) infusion.

Representative polyacrylamide/6% urea gels that demonstrate transferrin saturation (TSAT) for (A) a patient who was given the low-dosage (1.5 mg/kg) infusion.
Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)
Mean and median systolic and diastolic BPs after dialysis were unchanged over time and similar between epoetin alfa-epbx and epoetin alfa. Mean and median.

Mean and median systolic and diastolic BPs after dialysis were unchanged over time and similar between epoetin alfa-epbx and epoetin alfa. Mean and median.

Similar presentations

Ads by Google